Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)Matthew J. Ellis, Kelly K. Hunt, Souzan Sanati et al.|Journal of Clinical Oncology|2017Cited by 411
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their CombinationX. Cynthia, Lisa A. Carey, Vera J. Suman et al.|JAMA Oncology|2024Cited by 20